Provenance du réseau au premier degré de Meg M. Silverman
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Thomas, McNerney & Partners LLC
 Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota.
1
| Extinct | Investment Managers | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Meg M. Silverman via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Warburg Pincus LLC
 Warburg Pincus LLC Investment ManagersFinance Warburg Pincus LLC (Warburg Pincus) is a private equity subsidiary of Warburg Pincus & Company US LLC founded in 1966. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
| University of Michigan | College/University | Undergraduate Degree | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal | |
| GLOBAL BLOOD THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Operating Officer | |
| EIDOS THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO | |
| Harvard Business School | College/University | Masters Business Admin | |
| The Bluefield Project to Cure Frontotemporal Dementia | Corporate Officer/Principal | ||
| MONTE ROSA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Chief Operating Officer | |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Bright Peak Therapeutics, Inc.
 Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 14 |
| Suisse | 2 |
Sectorielle
| Health Technology | 8 |
| Finance | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Opérationnelle
| Director/Board Member | 5 |
| Chief Operating Officer | 3 |
| Corporate Officer/Principal | 2 |
| Independent Dir/Board Member | 2 |
| Private Equity Analyst | 1 |
Relations les plus connectées
| Insiders | |
|---|---|
| Christine Siu | 15 |
- Bourse
- Insiders
- Meg M. Silverman
- Connexions Sociétés
